LY3475070
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for LY3475070, covering 2024-04-05 to 2024-04-05. Get the full timeline:
Most recent: Clinical Trial Update: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer [Phase 1]